SIRT2 and melanoma: Interestingly, Karwaciak et al. [31] demonstrated that downregulation of SIRT2 in melanoma cell lines sensitized them to dasatinib, decreased mRNA and protein expression of EphA2, and altered mRNA expression of several other kinase target genes of dasatinib.